Literature DB >> 25342129

Dysfunctionally phosphorylated type 1 insulin receptor substrate in neural-derived blood exosomes of preclinical Alzheimer's disease.

Dimitrios Kapogiannis1, Adam Boxer2, Janice B Schwartz3, Erin L Abner4, Arya Biragyn1, Umesh Masharani5, Lynda Frassetto5, Ronald C Petersen6, Bruce L Miller2, Edward J Goetzl7.   

Abstract

Insulin resistance causes diminished glucose uptake in similar regions of the brain in Alzheimer's disease (AD) and type 2 diabetes mellitus (DM2). Brain tissue studies suggested that insulin resistance is caused by low insulin receptor signaling attributable to its abnormal association with more phospho (P)-serine-type 1 insulin receptor substrate (IRS-1) and less P-tyrosine-IRS-1. Plasma exosomes enriched for neural sources by immunoabsorption were obtained once from 26 patients with AD, 20 patients with DM2, 16 patients with frontotemporal dementia (FTD), and matched case control subjects. At 2 time points, they were obtained from 22 others when cognitively normal and 1 to 10 yr later when diagnosed with AD. Mean exosomal levels of extracted P-serine 312-IRS-1 and P-pan-tyrosine-IRS-1 by ELISA and the ratio of P-serine 312-IRS-1 to P-pan-tyrosine-IRS-1 (insulin resistance factor, R) for AD and DM2 and P-serine 312-IRS-1 and R for FTD were significantly different from those for case control subjects. The levels of R for AD were significantly higher than those for DM2 or FTD. Stepwise discriminant modeling showed correct classification of 100% of patients with AD, 97.5% of patients with DM2, and 84% of patients with FTD. In longitudinal studies of 22 patients with AD, exosomal levels of P-serine 312-IRS-1, P-pan-tyrosine-IRS-1, and R were significantly different 1 to 10 yr before and at the time of diagnosis compared with control subjects. Insulin resistance reflected in R values from this blood test is higher for patients with AD, DM2, and FTD than case control subjects; higher for patients with AD than patients with DM2 or FTD; and accurately predicts development of AD up to 10 yr prior to clinical onset. © FASEB.

Entities:  

Keywords:  dementia; insulin resistance; senescence

Mesh:

Substances:

Year:  2014        PMID: 25342129      PMCID: PMC4314222          DOI: 10.1096/fj.14-262048

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  39 in total

Review 1.  Critical nodes in signalling pathways: insights into insulin action.

Authors:  Cullen M Taniguchi; Brice Emanuelli; C Ronald Kahn
Journal:  Nat Rev Mol Cell Biol       Date:  2006-02       Impact factor: 94.444

2.  Classification of primary progressive aphasia and its variants.

Authors:  M L Gorno-Tempini; A E Hillis; S Weintraub; A Kertesz; M Mendez; S F Cappa; J M Ogar; J D Rohrer; S Black; B F Boeve; F Manes; N F Dronkers; R Vandenberghe; K Rascovsky; K Patterson; B L Miller; D S Knopman; J R Hodges; M M Mesulam; M Grossman
Journal:  Neurology       Date:  2011-02-16       Impact factor: 9.910

3.  Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline.

Authors:  Konrad Talbot; Hoau-Yan Wang; Hala Kazi; Li-Ying Han; Kalindi P Bakshi; Andres Stucky; Robert L Fuino; Krista R Kawaguchi; Andrew J Samoyedny; Robert S Wilson; Zoe Arvanitakis; Julie A Schneider; Bryan A Wolf; David A Bennett; John Q Trojanowski; Steven E Arnold
Journal:  J Clin Invest       Date:  2012-04       Impact factor: 14.808

Review 4.  Positive and negative regulation of insulin signaling through IRS-1 phosphorylation.

Authors:  Philippe Gual; Yannick Le Marchand-Brustel; Jean-François Tanti
Journal:  Biochimie       Date:  2005-01       Impact factor: 4.079

5.  The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts.

Authors:  Stefan J Cano; Holly B Posner; Margaret L Moline; Stephen W Hurt; Jina Swartz; Tim Hsu; Jeremy C Hobart
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-09-29       Impact factor: 10.154

6.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Authors:  Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

7.  Insulin resistance and Alzheimer's disease: molecular links & clinical implications.

Authors:  Karen F Neumann; Leonel Rojo; Leonardo P Navarrete; Gonzalo Farías; Paula Reyes; Ricardo B Maccioni
Journal:  Curr Alzheimer Res       Date:  2008-10       Impact factor: 3.498

8.  Glucose levels and risk of dementia.

Authors:  Paul K Crane; Rod Walker; Rebecca A Hubbard; Ge Li; David M Nathan; Hui Zheng; Sebastien Haneuse; Suzanne Craft; Thomas J Montine; Steven E Kahn; Wayne McCormick; Susan M McCurry; James D Bowen; Eric B Larson
Journal:  N Engl J Med       Date:  2013-08-08       Impact factor: 91.245

Review 9.  Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2.

Authors:  K D Copps; M F White
Journal:  Diabetologia       Date:  2012-08-08       Impact factor: 10.122

10.  Common inhibitory serine sites phosphorylated by IRS-1 kinases, triggered by insulin and inducers of insulin resistance.

Authors:  Avia Herschkovitz; Yan-Fang Liu; Erez Ilan; Denise Ronen; Sigalit Boura-Halfon; Yehiel Zick
Journal:  J Biol Chem       Date:  2007-04-19       Impact factor: 5.157

View more
  139 in total

Review 1.  GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies.

Authors:  Parker H Johnson; Neal J Weinreb; James C Cloyd; Paul J Tuite; Reena V Kartha
Journal:  Mol Genet Metab       Date:  2019-10-23       Impact factor: 4.797

Review 2.  (-)-Phenserine and Inhibiting Pre-Programmed Cell Death: In Pursuit of a Novel Intervention for Alzheimer's Disease.

Authors:  Robert E Becker; Nigel H Greig; Debomoy K Lahiri; Joseph Bledsoe; Sarah Majercik; Clive Ballard; Dag Aarsland; Lon S Schneider; Douglas Flanagan; Ramprakash Govindarajan; Mary Sano; Luigi Ferrucci; Dimitrios Kapogiannis
Journal:  Curr Alzheimer Res       Date:  2018       Impact factor: 3.498

Review 3.  Emerging roles of extracellular vesicles in neurodegenerative disorders.

Authors:  Yang You; Tsuneya Ikezu
Journal:  Neurobiol Dis       Date:  2019-06-20       Impact factor: 5.996

4.  Plasma α-synuclein and cognitive impairment in the Parkinson's Associated Risk Syndrome: A pilot study.

Authors:  Hua Wang; Anzari Atik; Tessandra Stewart; Carmen Ginghina; Patrick Aro; Kathleen F Kerr; John Seibyl; Danna Jennings; Poul Henning Jensen; Kenneth Marek; Min Shi; Jing Zhang
Journal:  Neurobiol Dis       Date:  2018-04-27       Impact factor: 5.996

Review 5.  Programming apoptosis and autophagy with novel approaches for diabetes mellitus.

Authors:  Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2015       Impact factor: 1.990

Review 6.  Exosome release and cargo in Down syndrome.

Authors:  Eric D Hamlett; Angela LaRosa; Elliott J Mufson; Juan Fortea; Aurélie Ledreux; Ann-Charlotte Granholm
Journal:  Dev Neurobiol       Date:  2019-08-06       Impact factor: 3.964

7.  Neuronal Enriched Extracellular Vesicle Proteins as Biomarkers for Traumatic Brain Injury.

Authors:  Hanuma Kumar Karnati; Joseph H Garcia; David Tweedie; Robert E Becker; Dimitrios Kapogiannis; Nigel H Greig
Journal:  J Neurotrauma       Date:  2018-10-25       Impact factor: 5.269

8.  Altered levels of plasma neuron-derived exosomes and their cargo proteins characterize acute and chronic mild traumatic brain injury.

Authors:  Edward J Goetzl; Fanny M Elahi; Maja Mustapic; Dimitrios Kapogiannis; Moira Pryhoda; Anah Gilmore; Kimberly A Gorgens; Bradley Davidson; Anne-Charlotte Granholm; Aurélie Ledreux
Journal:  FASEB J       Date:  2019-01-03       Impact factor: 5.191

Review 9.  Astrocyte-derived extracellular vesicles: Neuroreparative properties and role in the pathogenesis of neurodegenerative disorders.

Authors:  Raghavendra Upadhya; Winston Zingg; Siddhant Shetty; Ashok K Shetty
Journal:  J Control Release       Date:  2020-04-11       Impact factor: 9.776

Review 10.  Sphingolipid-Enriched Extracellular Vesicles and Alzheimer's Disease: A Decade of Research.

Authors:  Michael B Dinkins; Guanghu Wang; Erhard Bieberich
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.